Literature DB >> 16767748

Developmental regulation of cardiac MAP4 protein expression.

Daniel R Webster1, Jason M Bratcher.   

Abstract

It has been shown that the level of expression of microtubule-associated protein 4 (MAP4) mRNAs changes throughout neonatal heart development [Chapin SJ, et al. 1995. Biochemistry 34:2289]. In the present study, both immunofluorescence and western blotting methods were used to monitor MAP4 protein expression levels in the developing heart. By both methods, it was shown that the levels of total MAP4 protein were maximal during the first postnatal week, and then declined progressively to adulthood. In addition, four major electrophoretic species that reacted with MAP4-specific antibodies (called bands 1-4) were observed in all heart tissue samples. Three of the four bands decreased in abundance throughout postnatal development, but at different rates. The fourth band remained relatively constant in abundance with increasing postnatal age. To determine if phosphorylation events might contribute to this heterogeneity, western blotting experiments using phospho-specific antibodies and phosphatase digestion of extract samples were performed. No phosphorylation-specific antibody staining was observed and no significant changes were demonstrated in the bands after phosphatase treatment, implying that the observed complexity was due mainly to alternative start site or differential isoform expression. Finally, it was discovered that cardiomyocyte MAP4 associated with drug- and cold-stable microtubules in early neonatal myocytes. Thus, the complex regulation of MAP4 protein expression may play a key role in the functional differentiation of myocyte microtubules during heart development. Copyright 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16767748     DOI: 10.1002/cm.20140

Source DB:  PubMed          Journal:  Cell Motil Cytoskeleton        ISSN: 0886-1544


  4 in total

1.  Calpain 6 is involved in microtubule stabilization and cytoskeletal organization.

Authors:  Kazuo Tonami; Yukiko Kurihara; Hiroyuki Aburatani; Yasunobu Uchijima; Tomoichiro Asano; Hiroki Kurihara
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

2.  Genetic drivers of m6A methylation in human brain, lung, heart and muscle.

Authors:  Xushen Xiong; Lei Hou; Yongjin P Park; Benoit Molinie; Richard I Gregory; Manolis Kellis
Journal:  Nat Genet       Date:  2021-07-01       Impact factor: 41.307

3.  P38/MAPK contributes to endothelial barrier dysfunction via MAP4 phosphorylation-dependent microtubule disassembly in inflammation-induced acute lung injury.

Authors:  Lingfei Li; Jiongyu Hu; Ting He; Qiong Zhang; Xu Yang; Xiaodong Lan; Dongxia Zhang; Hao Mei; Bing Chen; Yuesheng Huang
Journal:  Sci Rep       Date:  2015-03-09       Impact factor: 4.379

4.  CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.

Authors:  Sara A Wickström; Katarzyna C Masoumi; Saadi Khochbin; Reinhard Fässler; Ramin Massoumi
Journal:  EMBO J       Date:  2009-11-05       Impact factor: 11.598

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.